LPN
2021-08-05
Wow
Why Moderna Stock Surged to a New All-Time High Today
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":890709045,"tweetId":"890709045","gmtCreate":1628131289487,"gmtModify":1631889356892,"author":{"id":3578563881684908,"idStr":"3578563881684908","authorId":3578563881684908,"authorIdStr":"3578563881684908","name":"LPN","avatar":"https://static.tigerbbs.com/63e3cb5f66016a665aadbe18eaadb09b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":27,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Wow</p></body></html>","htmlText":"<html><head></head><body><p>Wow</p></body></html>","text":"Wow","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/890709045","repostId":1105353628,"repostType":4,"repost":{"id":"1105353628","pubTimestamp":1628127525,"share":"https://www.laohu8.com/m/news/1105353628?lang=&edition=full","pubTime":"2021-08-05 09:38","market":"us","language":"en","title":"Why Moderna Stock Surged to a New All-Time High Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1105353628","media":"The Motley Fool","summary":"Mounting COVID-19 case counts could drive more people to get vaccinated.\nWhat happened\nShares of Mod","content":"<p><i>Mounting COVID-19 case counts could drive more people to get vaccinated.</i></p>\n<h3><b>What happened</b></h3>\n<p>Shares of <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped 8.4% to a record closing high of $419.05 on Wednesday, as investors bid up the biotech's stock price ahead of its upcoming earnings announcement.</p>\n<h3><b>So what</b></h3>\n<p>Moderna said on Tuesday that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its mRNA vaccine candidate against respiratory syncytial virus (RSV) in adults older than 60. RSV is a common respiratory virus that leads to roughly 177,000 hospitalizations and 14,000 deaths among adults 65 years and older each year, according to the U.S. Centers for Disease Control and Prevention.</p>\n<p>The Fast Track designation will accelerate the FDA's review of Moderna's drug. If the vaccine proves both safe and effective, Moderna could add a new revenue stream sooner than many investors expected.</p>\n<p><img src=\"https://static.tigerbbs.com/0b073ade8c6474ded744f2354f61f137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Meanwhile, surging COVID-19 case counts, driven by the spread of the highly contagious delta variant, are leading government officials to reimpose mask-wearing mandates and other safety restrictions. New York City, for one, said it would require evidence of a coronavirus vaccination before people could work out at gyms and dine indoors at restaurants. Many businesses and universities also plan to require proof of vaccination from their employees and students.</p>\n<h3><b>Now what</b></h3>\n<p>Investors appear to be betting that these mandates will increase demand for Moderna's COVID-19 vaccine. Shareholders can expect management to provide its most up-to-date sales and earnings forecast tomorrow. Moderna is slated to hold its second-quarter earnings call at 8 a.m. EDT.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Surged to a New All-Time High Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Surged to a New All-Time High Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 09:38 GMT+8 <a href=https://www.fool.com/investing/2021/08/04/why-moderna-stock-surged-to-a-new-all-time-high-to/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mounting COVID-19 case counts could drive more people to get vaccinated.\nWhat happened\nShares of Moderna, Inc. jumped 8.4% to a record closing high of $419.05 on Wednesday, as investors bid up the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/why-moderna-stock-surged-to-a-new-all-time-high-to/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/04/why-moderna-stock-surged-to-a-new-all-time-high-to/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105353628","content_text":"Mounting COVID-19 case counts could drive more people to get vaccinated.\nWhat happened\nShares of Moderna, Inc. jumped 8.4% to a record closing high of $419.05 on Wednesday, as investors bid up the biotech's stock price ahead of its upcoming earnings announcement.\nSo what\nModerna said on Tuesday that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its mRNA vaccine candidate against respiratory syncytial virus (RSV) in adults older than 60. RSV is a common respiratory virus that leads to roughly 177,000 hospitalizations and 14,000 deaths among adults 65 years and older each year, according to the U.S. Centers for Disease Control and Prevention.\nThe Fast Track designation will accelerate the FDA's review of Moderna's drug. If the vaccine proves both safe and effective, Moderna could add a new revenue stream sooner than many investors expected.\nIMAGE SOURCE: GETTY IMAGES.\nMeanwhile, surging COVID-19 case counts, driven by the spread of the highly contagious delta variant, are leading government officials to reimpose mask-wearing mandates and other safety restrictions. New York City, for one, said it would require evidence of a coronavirus vaccination before people could work out at gyms and dine indoors at restaurants. Many businesses and universities also plan to require proof of vaccination from their employees and students.\nNow what\nInvestors appear to be betting that these mandates will increase demand for Moderna's COVID-19 vaccine. Shareholders can expect management to provide its most up-to-date sales and earnings forecast tomorrow. Moderna is slated to hold its second-quarter earnings call at 8 a.m. EDT.","news_type":1},"isVote":1,"tweetType":1,"viewCount":123,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/890709045"}
精彩评论